Dogwood Therapeutics, Inc.
NASDAQ:DWTXBiotechnology
+$0.04 today
- Market cap
- $51.12M
- Beta
- 1.76
- P/E (TTM)
- -0.2
- EPS (TTM)
- -$0.84
Volume 0.12M
Average 0.09M
DWTX Operating Expenses
Total costs of running the business that are not directly tied to producing goods or services sold.
Dogwood Therapeutics, Inc.NASDAQ: DWTX
Operating Expenses · Q1 FY2026 · quarter ended Mar 2026
Operating expenses grows, but more slowly than its trailing trend
Q1 FY2026 operating expenses of $5.08M rose 14.6% year over year, behind the +86.5% change in trailing-twelve-month operating expenses. Sequentially, it rose 33.4% from the prior quarter. Over 3 fiscal years it compounded at +31.4% a year.
Context
- Operating expenses increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +14.6% toward the trailing-twelve-month pace of +86.5%.
Sources:Income StatementText generated from reported figures; not investment advice.
Operating Expenses history
USD · from the income statement
- Latest · FY2025
- 27.97M USD
- Year-over-year change
- +128.7%
- 4-year CAGR
- +15.6%
| Period | Period end | Operating Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 27.97M | +128.7% |
| FY2024 | 2024-12-31 | 12.23M | +124.5% |
| FY2023 | 2023-12-31 | 5.45M | -55.8% |
| FY2022 | 2022-12-31 | 12.32M | -21.3% |
| FY2021 | 2021-12-31 | 15.64M | — |
Operating Expenses vs competitors
How DWTX compares with its peers on the latest reported figures
- DWTX's LTM Mar 2026 operating expenses of $28.61M is the highest of the 2 companies compared; the peer median is $10.94M.
- Its year-over-year change of +86.5% is the highest of 2, against a peer median of +68.9%.
- Over three fiscal years its annual growth of +31.4% compares with a peer median of -24.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $28.61M | +86.5% | +31.4% | — | |
| LTM Mar 2026 | $10.94M | +68.9% | -24.9% | — | |
| Peer median (excluding DWTX) | $10.94M | +68.9% | -24.9% | — | |
Competitors are the stored peer set for DWTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 10.8M | 8.07M | 1.73M | 3.53M | 21.87M |
| Selling, General & Admin | 4.85M | 4.25M | 3.72M | 8.7M | 6.1M |
| Operating Expenses | 15.64M | 12.32M | 5.45M | 12.23M | 27.97M |
| Depreciation & Amortization | 0 | 0 | 0 | 12.18K | 2.06K |
| EBITDA | (15.96M) | (12.25M) | (5.3M) | (12.25M) | (34.03M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (15.64M) | (12.32M) | (5.45M) | (12.23M) | (27.97M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 5.67K | 67.48K | 150.9K | 0 | 96.94K |
| Interest Expense | 0 | 0 | 0 | 92.19K | 0 |
| Other Income / Expenses | (319.33K) | 67.48K | 150.9K | (122.98K) | (6.07M) |
| Income Before Tax | (15.96M) | (12.25M) | (5.3M) | (12.35M) | (34.04M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | (503) | 221.1K |
| Net Income | (15.96M) | (12.25M) | (5.3M) | (12.35M) | (34.26M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (47.90) | (27.66) | (7.05) | (12.52) | (4.32) |
| EPS (Diluted) | (47.90) | (27.66) | (7.05) | (12.52) | (4.32) |
| Weighted Avg Shares | 333.17K | 442.8K | 751.07K | 1.03M | 8.22M |
| Weighted Avg Shares (Diluted) | 333.17K | 442.8K | 751.07K | 1.03M | 8.22M |
Dogwood Therapeutics, Inc.
NASDAQ:DWTX
Intrinsic Alpha fair value
Locked
Current Price
$1.52
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.